- Home
- ESRT vs ATAI Comparison
ESRT vs ATAI Comparison
Compare ESRT & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESRT | ATAI |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2012 | 2025 |
Fundamental Metrics
Financial Performance| Metric | ESRT | ATAI |
|---|---|---|
| Price | $5.20 | $3.67 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $6.77 | ★ $15.13 |
| AVG Volume (30 Days) | 1.5M | ★ 3.5M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.71% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $768,270,000.00 | $4,089,000.00 |
| Revenue This Year | $4.26 | N/A |
| Revenue Next Year | $1.52 | N/A |
| P/E Ratio | $20.66 | ★ N/A |
| Revenue Growth | 0.05 | ★ 1227.60 |
| 52 Week Low | $4.87 | $1.28 |
| 52 Week High | $8.76 | $6.73 |
Technical Indicators
Market Signals| Indicator | ESRT | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 45.16 | 49.57 |
| Support Level | $4.87 | $3.60 |
| Resistance Level | $6.70 | $4.30 |
| Average True Range (ATR) | 0.16 | 0.19 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 74.42 | 56.74 |
Price Performance
Historical ComparisonAbout ESRT Empire State Realty Trust Inc.
Empire State Realty Trust operates as a pure-play greater New York and Manhattan-focused REIT, featuring its landmark Empire State Building office and observation deck. The company owns and operates around 8.5 million square feet of office space, about 80% of which is located in Manhattan.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.